Search
forLearn
5 / 801 resultslearn PTT-6®
learn propylparaben IP
learn ORPL
learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Research
5 / 1000+ results
research The effect of oxygen supply using perfluorocarbon-based nanoemulsions on human hair growth
A new nanoemulsion increases oxygen for hair cells, leading to better hair growth.
research Semifluorinated Alkanes as New Drug Carriers—An Overview of Potential Medical and Clinical Applications
Semifluorinated alkanes are promising for delivering drugs in various medical applications.
research Deep Insight of Design, Mechanism, and Cancer Theranostic Strategy of Nanozymes
Nanozymes show promise for effective and safe cancer treatment.
research Mitogen‐regulated protein/proliferin mRNA induction following single applications of tumor promoters to murine skin
mrp/plf-mRNA can indicate tumor-promoting effects in skin.
research Carbobenzoxy-capped Phe-Lys(BODIPY TMR-X-acyloxymethyl ketone(QSY7)
Near-infrared probes can safely and effectively image cysteine protease activity for disease diagnosis.
Community Join
5 / 1000+ resultscommunity Pp405 any site for buying in Europe
PP405 is not commercially available or legitimate in Europe. Users are discussing the lack of availability of this product.
community Petition Alert: Let's Get PP405 Phase 3 Trials in Germany by 2026!
A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.
community PP405 is nothing but a scam and Pelage know it.
PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.
community Why doesn't phase 3 of PP405 start straight away?
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.